

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Attorney Docket Number	4239-82094-06
Application Number	10/571,012
Filing Date	March 8, 2006
First Named Inventor	Cuttitta
Art Unit	1614
Examiner Name	Anna Pagonakis

## **U.S. PATENT DOCUMENTS**

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date and submit a copy.

Examiner's Initials*	Cite No. (optional)	Number	Date	Name of Applicant or Patentee
	A1	5,830,703	11/3/1998	Kitamura <i>et al.</i>
	A2	5,837,823	11/17/1998	Kitamura <i>et al.</i>
	A3	5,910,416	6/8/1999	Kitamura <i>et al.</i>
	A4	6,320,022	11/20/2001	Cuttitta <i>et al.</i>
	A5	6,440,421	8/27/2002	Cornish <i>et al.</i>
	A6	7,101,548	9/5/2006	Cuttitta <i>et al.</i>
	A7	7,364,719	4/29/2008	Cuttitta <i>et al.</i>
	A8	7,462,593	12/9/2008	Cuttitta <i>et al.</i>
	A9	2007/0025915	2/1/2007	Cuttitta <i>et al.</i>

## **FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Country	Number	Date	Name of Applicant or Patentee
	B1	EP	0 926 238 A2	6/30/1999	Poste
	B2	EP	0 926 238 A3	11/22/2000	Poste
	B3	WIPO	WO 00/54805	9/21/2000	University of Maryland

EXAMINER  
SIGNATURE:

DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	4239-82094-06
	Application Number	10/571,012
	Filing Date	March 8, 2006
	First Named Inventor	Cuttitta
	Art Unit	1614
	Examiner Name	Anna Pagonakis

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
	C1	Avis <i>et al.</i> , "Effect of Gastrin-Releasing Peptide on the Pancreatic Tumor Cell Line (Capan), <i>Molecular Carcinogenesis</i> , 8:214-220, 1993
	C2	Carney <i>et al.</i> , "Bombesin: A Potent Mitogen for Small Cell Lung Cancer," <i>Annals New York Academy of Sciences</i> , 547:303-309, 1988
	C3	Chaudry <i>et al.</i> , "Phase I and Imaging Trial of a Monoclonal Antibody Directed against Gastrin-releasing Peptide in Patients with Lung Cancer," <i>Clinical Cancer Research</i> , 5:3385-3393, 1999
	C4	Cuttitta <i>et al.</i> , "Adrenomedullin Functions as an Important Tumor Survival Factor in Human Carcinogenesis," <i>Microscopy Research and Technique</i> , 57:110-119, 2002
	C5	Cuttitta <i>et al.</i> , "Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer," <i>Nature</i> , 316:823-826, 1985
	C6	Giraud <i>et al.</i> , "Bombesin stimulation of gastrin release from canine gastrin cells in primary culture," <i>Am. J. Physiol.</i> , 252:G413-420, 1987
	C7	Heikkila <i>et al.</i> , "Bombesin-related Peptides Induce Calcium Mobilization in a Subset of Human Small Cell Lung Cancer Cell Lines," <i>The Journal of Biological Chemistry</i> , 262(34):16456-16460, 1987
	C8	Ishikawa <i>et al.</i> , "Adrenomedullin Antagonist Suppresses <i>in Vivo</i> Growth of Human Pancreatic Cancer Cells in SCID Mice by Suppressing Angiogenesis," <i>Oncogene</i> , 22:1238-1242, 2003
	C9	Ishimitsu <i>et al.</i> , "Genomic structure of human adrenomedullin gene," <i>Biochem. Biophys. Res. Commun.</i> , 203(1):631-639, 1994 <b>ABSTRACT ONLY</b>
	C10	Jongsma <i>et al.</i> , "Androgen-Independent Growth Is Induced by Neuropeptides in Human Prostate Cancer Cell Lines," <i>The Prostate</i> , 42:34-44, 2000
	C11	Julián <i>et al.</i> , "Adrenomedullin: a new target for the design of small molecular modulators with promising pharmacological activities," <i>European Journal of Medical Chemistry</i> , 40:737-750, 2005
	C12	Kamoi <i>et al.</i> , "Adrenomedullin inhibits the secretion of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, from rat alveolar macrophages," <i>Biochem. Biophys. Res. Commun.</i> , 211(3):1031-1035, 1995
	C13	Kanazawa <i>et al.</i> , "Adrenomedullin, a newly discovered hypotensive peptide, is a potent bronchodilator," <i>Biochem. Biophys. Res. Commun.</i> , 205(1):251-254, 1994
	C14	Kangawa <i>et al.</i> , "Adrenomedullin: a new hypotensive peptide," <i>J. Hypertens. Suppl.</i> , 14(5):S105-110, 1996 <b>ABSTRACT ONLY</b>

EXAMINER  
SIGNATURE:DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	4239-82094-06
	Application Number	10/571,012
	Filing Date	March 8, 2006
	First Named Inventor	Cuttitta
	Art Unit	1614
	Examiner Name	Anna Pagonakis

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
	C15	Kasprzyk <i>et al.</i> , "Solid-Phase Peptide Quantitation Assay Using Labeled Monoclonal Antibody and Glutaraldehyde Fixation," <i>Analytical Biochemistry</i> , 174:224-234, 1988
	C16	Kato <i>et al.</i> , "Adrenomedullin as an Autocrine/Paracrine Apoptosis Survival Factor for Rat Endothelial Cells," <i>Endocrinology</i> , 138(6):2615-2620, 1997
	C17	Kelley <i>et al.</i> , "Antitumor Activity of a Monoclonal Antibody Directed Against Gastrin-Releasing Peptide in Patients With Small Cell Lung Cancer," <i>Chest</i> , 112:256-261, 1997
	C18	Kitamura <i>et al.</i> , "Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma," <i>Biochem. Biophys. Res. Commun.</i> , 192(2):553-560, 1993
	C19	Lam <i>et al.</i> , "A new type of synthetic peptide library for identifying ligand-binding activity," <i>Nature</i> , 354:82-84, 1991
	C20	Lango <i>et al.</i> , "Gastrin-Releasing Peptide Receptor-Mediated Autocrine Growth in Squamous Cell Carcinoma of the Head and Neck," <i>Journal of the National Cancer Institute</i> , 94(5):375-383, 2002
	C21	Macpherson <i>et al.</i> , "Anti-angiogenic activity of human endostatin is HIF-1-independent <i>in vitro</i> and sensitive to timing of treatment in a human saphenous vein assay," <i>Molecular Cancer Therapeutics</i> , 2:845-854, 2003
	C22	Mantey <i>et al.</i> , "Rational Design of a Peptide Agonist That Interacts Selectively with the Orphan Receptor, Bombesin Receptor Subtype 3," <i>The Journal of Biological Chemistry</i> , 276(12):9219-9229, 2001
	C23	Martinez <i>et al.</i> , "Expression of Adrenomedullin in Normal Human Lung and in Pulmonary Tumors," <i>Endocrinology</i> , 136(9):4099-4105, 1995
	C24	Martinez <i>et al.</i> , "Regulation of Insulin Secretion and Blood Glucose Metabolism by Adrenomedullin," <i>Endocrinology</i> , 137(6):2626-2632, 1996
	C25	Martinez <i>et al.</i> , "Expression of Adrenomedullin and Its Receptor in Normal and Malignant Human Skin: A Potential Pluripotent Role in the Integument," <i>Endocrinology</i> , 138(12):5597-5604, 1997
	C26	Martinez <i>et al.</i> , "Is adrenomedullin a causal agent in some cases of type 2 diabetes?" <i>Peptides</i> , 20:1471-1478, 1999
	C27	Martinez <i>et al.</i> , "The Effects of Adrenomedullin Overexpression in Breast Tumor Cells," <i>Journal of the National Cancer Institute</i> , 94(16):1226-1237, 2002
	C28	Martinez <i>et al.</i> , "Identification of Vasoactive Nonpeptidic Positive and Negative Modulators of Adrenomedullin Using a Neutralizing Antibody-Based Screening Strategy," <i>Endocrinology</i> , 145(8):3858-3865, 2004

EXAMINER  
SIGNATURE:DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	4239-82094-06
	Application Number	10/571,012
	Filing Date	March 8, 2006
	First Named Inventor	Cuttitta
	Art Unit	1614
	Examiner Name	Anna Pagonakis

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
	C29	Martinez <i>et al.</i> , "Gastrin-releasing peptide (GRP) induces angiogenesis and the specific GRP blocker 77427 inhibits tumor growth <i>in vitro</i> and <i>in vivo</i> ," <i>Oncogene</i> , 24:4106-4113, 2005
	C30	Martinez, Alfredo, "A new family of angiogenic factors," <i>Cancer Letters</i> , 236:157-163, 2006
	C31	Merali <i>et al.</i> , "Role of bombesin-related peptides in the control of food intake," <i>Neuropeptides</i> , 33(5):376-386, 1999
	C32	Michibata <i>et al.</i> , "Autocrine/paracrine role of adrenomedullin in cultured endothelial and mesangial cells," <i>Kidney International</i> , 53:979-985, 1998
	C33	Miller <i>et al.</i> , "Adrenomedullin Expression in Human Tumor Cell Lines," <i>The Journal of Biological Chemistry</i> , 271(38):23345-23351, 1996
	C34	Moody <i>et al.</i> , "Adrenomedullin binds with high affinity, elevates cyclic AMP, and stimulates c-fos mRNA in C6 glioma cells," <i>Peptides</i> , 18(8):1111-1115, 1997 <b>ABSTRACT ONLY</b>
	C35	Mulshine <i>et al.</i> , "Autocrine Growth Factors as Therapeutic Targets in Lung Cancer," <i>Chest</i> , 96:31S-34S, 1989
	C36	Ohki-Hamazaki <i>et al.</i> , "Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity," <i>Nature</i> , 390:165-169, 1997
	C37	Ouafik <i>et al.</i> , "Neutralization of Adrenomedullin Inhibits the Growth of Human Glioblastoma Cell Lines <i>in Vitro</i> and Suppresses Tumor Xenograft Growth <i>in Vivo</i> ," <i>American Journal of Pathology</i> , 160(4):1279-1292, 2002
	C38	Parkes <i>et al.</i> , "ACTH-suppressive and vasodilator actions of adrenomedullin in conscious sheep," <i>J. Neuroendo.</i> , 7:923-929, 1995
	C39	Pío <i>et al.</i> , "Identification, Characterization, and Physiological Actions of Factor H as an Adrenomedullin Binding Protein Present in Human Plasma," <i>Microscopy Research and Technique</i> , 57:23-27, 2002
	C40	Poyner <i>et al.</i> , "International Union of Pharmacology.XXXII. The Mammalian Calcitonin Gene-Related Peptides, Adrenomedullin, Amylin, and Calcitonin Receptors," <i>Pharmacological Reviews</i> , 54(2):233-246, 2002

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	